Jayant Gadrey: Analysis of ongoing clinical trials of ADCs for patients with breast cancer brain metastases
Jayant Gadrey, Resident Physician at the Tufts Medical Center, shared a post on X by Ilana Schlam, Assistant Professor of Medicine at Tufts University Medical Center, about their recent paper published in Therapeutic Advances in Medical Oncology:
“Role of antibody drug conjugates in the treatment of patients with breast cancer brain metastases”
Authors: Stacey Pan, Jayant Gadrey, Sarah Sammons, Nancy Lin, Sara Tolaney, Paolo Tarantino, Ilana Schlam.
“Really happy to share that our review and analysis of ongoing clinical trials of ADCs for patients with breast cancer brain metastases is out now!
A thread of salient points and ideas of this article:
Brain metastasis is a devastating clinicopathologic manifestation of breast cancer progression. The median survival is grim, ranging from 4.5 to 13.2 months based on the underlying biological subset of breast cancer.
Treatment options have been historically limited to surgical resection, whole brain radiation, and stereotactic radiosurgery (depending on the clinical case). Excitingly, recent studies are beginning to show that ADCs may provide a new ray of hope for patients battling BCBM.
Herein, we reviewed and analyzed the ADCs and the clinical trials that identified the intracranial efficacies of ADCs in patients with BCBM.
We also tabulated the ongoing clinical trials of ADCs evaluating the efficacy against active BCBM, compiling the phases, enrollments, inclusion criteria, and primary and secondary outcomes.
Most importantly, we shed light on the incredible potential of retrospective subgroup analyses of early-stage clinical trials of novel ADCs in obtaining evidence of intracranial efficacy.
This, in turn, will help to identify the most promising ADCs that would be more likely to yield a positive read-out in clinical trials that are designed to prospectively assess intracranial efficacy against active BCBM lesions.
The success of this approach was recently demonstrated at ESMO 2024 when Dr. Nancy Lin presented the primary results of DB-12 with jaw-dropping CNS ORR rates of 71%, 82% in pts with untreated active BCBM, and 12-month OS >90%!
Given this, we have tabulated a comprehensive list of novel ADCs in early-stage clinical trials in which patients with stable, not active, BCBM lesions are eligible to participate. We have compiled the phases, enrollments, inclusion criteria, and primary and secondary outcomes.
We hope that this article will be a helpful resource to the breast cancer community at large. Here’s to leaving no stone unturned in our mission to develop more efficacious therapies for cancer patients.”
Quoting Ilana Schlam’s post:
“New review – ADCs for the treatment of breast cancer brain metastases (pre DB12).”
Jayant Gadrey is currently serving as a Resident Physician in Internal Medicine at Tufts Medical Center. He completed an MD with distinction from Wayne State University School of Medicine and BA in Biology with a focus on Molecular, Cellular Biology, and Genetics from Boston University.
Ilana Schlam, MD, is a breast medical oncologist and Assistant Professor of Medicine at Tufts University Medical Center. Her research focuses on precision medicine, drug development, and addressing healthcare disparities in breast cancer treatment and outcomes.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023